Peer Exchange

Our Peer Exchange™ program provides a multi-stakeholder perspective on important issues that providers, pharmacists, payers, and patients grapple with as they step into the world of biosimilars.
The panel identifies specific methods regarding the incorporation of biosimilars as treatment options in oncology.
Expert perspective on how to select a specific biosimilar when several might be available for the same reference biologic.
A brief review of how biosimilars might exist alongside novel or newly approved biologics.
Considerations for biosimilars from the standpoint of market access and how potential challenges are addressed.
The panel sheds light on how a biosimilar’s role in a formulary is determined.
Experts review available oncologic biosimilars and address practical concerns for initiating or switching over to biologic therapy.
Practical perspectives on the challenges related to bringing biosimilars to market.
Specific considerations for how the cost of biologics might make them a preferred option for patients.
Shared insight on the evidence backing biosimilars and their cost compared with biologics.
Comprehensive insight regarding the approval process, availability, and efficacy of biosimilars.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.